Medinol said today that it won CE Mark clearance for its EluNir drug-eluting stent – a device designed with a low metal footprint and a elastomeric coating.
In one 958-patient clinical study, the coronary stent had a 12-month target lesion failure rate of 5.4% and a 0% rate of late stent thrombosis, proving non-inferior to the Resolute zotarolimus-eluting stent.
Get the full story at our sister site, Drug Delivery Business News.
The post Medinol wins CE Mark for EluNir drug-eluting coronary stent system appeared first on MassDevice.